RU95113118A - Intestinal Duloxetine Granules - Google Patents

Intestinal Duloxetine Granules

Info

Publication number
RU95113118A
RU95113118A RU95113118/14A RU95113118A RU95113118A RU 95113118 A RU95113118 A RU 95113118A RU 95113118/14 A RU95113118/14 A RU 95113118/14A RU 95113118 A RU95113118 A RU 95113118A RU 95113118 A RU95113118 A RU 95113118A
Authority
RU
Russia
Prior art keywords
granules according
duloxetine
granules
layer
neutralized
Prior art date
Application number
RU95113118/14A
Other languages
Russian (ru)
Other versions
RU2147231C1 (en
Inventor
Роберт Андерсон Нил
Ллойд Оурен Питер
Огура Тосихиро
Фудзии Тосиро
Original Assignee
Эли Лилли Энд Компани
Сионоги энд Компани, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/276,232 external-priority patent/US5508276A/en
Application filed by Эли Лилли Энд Компани, Сионоги энд Компани, Лтд. filed Critical Эли Лилли Энд Компани
Publication of RU95113118A publication Critical patent/RU95113118A/en
Application granted granted Critical
Publication of RU2147231C1 publication Critical patent/RU2147231C1/en

Links

Claims (10)

1. Кишечные гранулы дульоксетина, отличающиеся тем, что состоят из: а) ядра, содержащего дульоксетина и фармацевтически приемлемый наполнитель; в) необязательно разделяющего слоя; с) кишечного слоя, содержащего ацетат-сукцинат гидроксипропилметилцеллюлозы (АСГПМЦ) и фармацевтически приемлемый наполнитель; d) необязательно завершающего слоя.1. Intestinal granules of duloxetine, characterized in that they consist of: a) a core containing duloxetine and a pharmaceutically acceptable excipient; c) optionally separating layer; c) an intestinal layer containing hydroxypropyl methylcellulose acetate succinate (ACHPMC) and a pharmaceutically acceptable excipient; d) optionally a final layer. 2. Гранулы по п. 1, отличающиеся тем, что АСГПМЦ частично нейтрализован ионами аммония до степени, при которой нейтрализуется 0 - 25% групп янтарной кислоты. 2. Granules according to claim 1, characterized in that the HPMC is partially neutralized by ammonium ions to the extent that 0 - 25% of succinic acid groups are neutralized. 3. Гранулы по п. 2, отличающиеся тем, что АСГПМЦ частично нейтрализован до степени, при которой нейтрализуется 0-15% групп янтарной кислоты. 3. Granules according to claim 2, characterized in that the HPMC is partially neutralized to the extent that 0-15% of succinic acid groups are neutralized. 4. Гранулы по п. 1, отличающиеся тем, что в них присутствует разделяющий слой. 4. Granules according to claim 1, characterized in that a separating layer is present in them. 5. Гранулы по п. 1, отличающиеся тем, что средний размер частиц дульоксетина 50 мкм или менее. 5. Granules according to claim 1, characterized in that the average particle size of duloxetine is 50 μm or less. 6. Гранулы по п. 5, отличающиеся тем, что ядро представляет собой инертный шарик, на котором нанесен слой дульоксетина, слой содержит дополнительно фармацевтически приемлемый носитель. 6. Granules according to claim 5, characterized in that the core is an inert ball on which a layer of duloxetine is applied, the layer further comprises a pharmaceutically acceptable carrier. 7. Гранулы по п.6, отличающиеся тем, что в них присутствует разделяющий слой. 7. Granules according to claim 6, characterized in that a separating layer is present in them. 8. Гранулы по п. 7, отличающиеся тем, что АСГПМЦ частично нейтрализован ионами аммония до степени, при которой нейтрализуется 0 - 25% групп янтарной кислоты. 8. Granules according to claim 7, characterized in that the HPMC is partially neutralized by ammonium ions to the extent that 0 to 25% of succinic acid groups are neutralized. 9. Гранулы по п. 4, отличающиеся тем, что разделяющий слой содержит фармацевтически приемлемый сахар. 9. Granules according to claim 4, characterized in that the separating layer contains a pharmaceutically acceptable sugar. 10. Гранулы по п. 9, отличающиеся тем, что сахар представлен сахарозой. 10. Granules according to claim 9, characterized in that the sugar is sucrose.
RU95113118A 1994-07-18 1995-07-17 Intestinal duloxetine granules RU2147231C1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/276,232 US5508276A (en) 1994-07-18 1994-07-18 Duloxetine enteric pellets
US08/276,232 1994-07-18

Publications (2)

Publication Number Publication Date
RU95113118A true RU95113118A (en) 1997-12-10
RU2147231C1 RU2147231C1 (en) 2000-04-10

Family

ID=23055767

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95113118A RU2147231C1 (en) 1994-07-18 1995-07-17 Intestinal duloxetine granules

Country Status (30)

Country Link
US (1) US5508276A (en)
EP (1) EP0693282B1 (en)
JP (1) JP3707831B2 (en)
KR (1) KR100356240B1 (en)
CN (1) CN1106191C (en)
AT (1) ATE200620T1 (en)
AU (1) AU686384B2 (en)
BR (1) BR9503346A (en)
CA (1) CA2153856C (en)
CO (1) CO4410177A1 (en)
CZ (1) CZ288095B6 (en)
DE (1) DE69520711T2 (en)
DK (1) DK0693282T3 (en)
ES (1) ES2157297T3 (en)
GE (1) GEP20063944B (en)
GR (1) GR3036185T3 (en)
HU (1) HU221502B (en)
IL (1) IL114584A (en)
MY (1) MY116361A (en)
NO (2) NO312397B1 (en)
NZ (1) NZ272554A (en)
PE (1) PE32196A1 (en)
PL (1) PL181296B1 (en)
PT (1) PT693282E (en)
RU (1) RU2147231C1 (en)
SI (1) SI0693282T1 (en)
TW (1) TW382596B (en)
UA (1) UA41344C2 (en)
YU (1) YU49445B (en)
ZA (1) ZA955799B (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9800589A (en) * 1995-07-24 1998-04-30 Lilly Co Eli Treatment of attention-deficit/hyperactivity disorder.
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
DE69941712D1 (en) 1998-09-15 2010-01-07 Lilly Co Eli USE OF DULOXETINES FOR THE TREATMENT OF FIBROMYALGIA
ES2306646T3 (en) * 1999-02-09 2008-11-16 Pfizer Products Inc. COMPOSITIONS OF BASIC PHARMACOS WITH INCREASED BIODISPONIBILITY.
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
SK12812002A3 (en) * 2000-03-07 2003-08-05 Eli Lilly And Company Treatment of psoriasis
JP2004525940A (en) * 2001-03-29 2004-08-26 イーライ・リリー・アンド・カンパニー Duloxetine for the treatment of hot flashes
ATE444060T1 (en) 2001-06-22 2009-10-15 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS CONTAINING DISPERSIONS OF MEDICINAL SUBSTANCES AND NEUTRAL POLYMERS
DE60237602D1 (en) * 2001-06-22 2010-10-21 Bend Res Inc PHARMACEUTICAL COMPOSITION CONTAINING HEAVY SOLUBLE AND ACIDIC TOXIC SUBSTANCES AND NEUTRALIZED ANIONIC POLYMERS
JP2006508978A (en) * 2002-11-19 2006-03-16 イーライ・リリー・アンド・カンパニー Treatment of gastrointestinal disorders with duloxetine
RU2351315C2 (en) * 2003-07-24 2009-04-10 Смитклайн Бичам Корпорейшн Films, dissolving in mouth cavity
KR20120136430A (en) * 2004-04-08 2012-12-18 교와 핫꼬 기린 가부시키가이샤 Solid pharmaceutical preparation with improved stability and process for producing the same
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
WO2006071868A2 (en) * 2004-12-23 2006-07-06 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
MX2007010931A (en) * 2005-03-08 2007-10-16 Teva Pharma Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2- thienyl) propanamine oxalate and the preparation thereof.
US7534900B2 (en) * 2005-03-14 2009-05-19 Teva Pharmaceutical Industries Ltd Process for the purification of duloxetine hydrochloride
JP2008543929A (en) * 2005-06-20 2008-12-04 カディラ・ヘルスケア・リミテッド Duloxetine controlled release dosage formulation
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
ES2434416T3 (en) 2005-08-10 2013-12-16 Add Advanced Drug Delivery Technologies, Ltd. Oral preparation with controlled release
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
US20080207923A1 (en) * 2005-09-22 2008-08-28 Santiago Ini Pure DNT-maleate and methods of preparation thereof
EP1838692A2 (en) * 2005-09-22 2007-10-03 Teva Pharmaceutical Industries Ltd Dnt-maleate and methods of preparation thereof
CA2629800A1 (en) * 2005-11-23 2007-05-31 Thomas G. Gant Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
DE102005060393A1 (en) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Pharmaceutical pellet, useful for the production of tablet, comprises a spherical active agent, preferably metroprololsuccinate, comprising core with smooth surface and a coat on the core, where the active agent release is pH-independent
EP1844034A1 (en) * 2006-01-23 2007-10-17 Teva Pharmaceutical Industries Ltd Dnt-fumarate and methods of preparation thereof
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation
KR200416582Y1 (en) 2006-03-07 2006-05-19 김정배 Shoes with stretching function
WO2007139886A2 (en) * 2006-05-22 2007-12-06 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride delayed release formulations
MX2008001079A (en) * 2006-05-23 2008-03-19 Teva Pharma Duloxetine hcl polymorphs.
JP5052051B2 (en) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 Enteric granules and method for producing the same
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
CN101190208B (en) * 2006-11-30 2011-11-02 石药集团中奇制药技术（石家庄）有限公司 Medicinal preparations containing duloxetine hydrochloride and preparation method thereof
WO2008077645A1 (en) 2006-12-22 2008-07-03 Synthon B.V. Process for making duloxetine and related compounds
EP2018860A1 (en) * 2007-07-16 2009-01-28 LEK Pharmaceuticals D.D. Duloxetine composition
BRPI0720958A2 (en) * 2006-12-27 2014-03-18 Lek Pharmaceuticals DULOXETINE OPPOSITION
EP1938840A1 (en) * 2006-12-27 2008-07-02 LEK Pharmaceuticals D.D. Duloxetine composition
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
US9358213B2 (en) * 2007-04-20 2016-06-07 Wockhardt Limited Pharmaceutical compositions of duloxetine
US20100172972A1 (en) * 2007-05-21 2010-07-08 Sun Pharmaceutical Industries Limited Enteric coated pharmaceutical compositions
GB0712220D0 (en) * 2007-06-23 2007-08-01 Arrow Int Ltd Duloxetine formulation
WO2009066181A2 (en) * 2007-07-09 2009-05-28 Combino Pharm, S.L. Oral delayed-release duloxentine hydrochloride pellets
US20090017113A1 (en) * 2007-07-13 2009-01-15 Osinga Niels J Duloxetine formulations
WO2009087657A2 (en) * 2007-11-03 2009-07-16 Alkem Laboratories Ltd. Stable pharmaceutical composition of duloxetine and process for its preparation
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
US9724362B2 (en) * 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
JP2011510024A (en) * 2008-01-25 2011-03-31 アルファファーム ピーティーワイ リミテッド Delayed release pharmaceutical composition of duloxetine
US20090226517A1 (en) * 2008-02-06 2009-09-10 Vinita Umashankar Vyas Pharmaceutical formulations comprising duloxetine
US20110020439A1 (en) * 2008-03-24 2011-01-27 Shrenik Annasaheb Kole Delayed release compositions of duloxetine
US20110038933A1 (en) * 2008-05-06 2011-02-17 Dexcell Ltd. Stable benzimidazole formulation
EP2133072A1 (en) 2008-06-13 2009-12-16 KRKA, D.D., Novo Mesto Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives
US20100040680A1 (en) * 2008-08-15 2010-02-18 Felix Lai Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation
ES2376095B1 (en) * 2008-10-02 2013-01-24 Laboratorios Del Dr. Esteve, S.A. ENERGY PELLETS OF DULOXETINE.
CN101756960B (en) * 2008-12-26 2012-06-27 上海中西制药有限公司 Duloxetine enteric-coated preparation and core material and preparation method thereof
WO2010078878A1 (en) * 2009-01-12 2010-07-15 Synthon B.V. Duloxetine formulations
US8758779B2 (en) * 2009-06-25 2014-06-24 Wockhardt Ltd. Pharmaceutical composition of duloxetine
DE102009033621A1 (en) 2009-07-17 2011-01-20 Add Technologies Ltd. Separating layers for pharmaceutical preparations for preventing interactions between drugs and pharmaceutical-technological excipients
MX2012003082A (en) * 2009-09-17 2012-04-19 Cadila Healthcare Ltd Pharmaceutical compositions for reducing alcohol-induced dose dumping.
US10071059B2 (en) * 2009-12-18 2018-09-11 Frieslandcampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
CA2792523C (en) * 2010-03-09 2018-01-09 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
EP2377525A1 (en) 2010-03-26 2011-10-19 Laboratorios del Dr. Esteve S.A. Duloxetine enteric pellets
ES2601841T3 (en) * 2010-05-25 2017-02-16 Hetero Research Foundation Duloxetine oral pharmaceutical composition
CN102908331A (en) * 2011-08-01 2013-02-06 浙江九洲药物科技有限公司 Duloxetine hydrochloride enteric capsules and preparation method thereof
HUE036187T2 (en) 2012-04-30 2018-06-28 Tillotts Pharma Ag A delayed release drug formulation
CA2870134C (en) 2012-05-02 2020-04-28 Capsugel France SAS Aqueous dispersions of hydroxypropyl methylcellulose acetate succinate (hpmcas)
CN103505421B (en) * 2012-06-29 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 A kind of enteric coated pellets formulation of duloxetine hydrochloride
CN103211777A (en) * 2013-03-31 2013-07-24 北京万全阳光医学技术有限公司 Pharmaceutic preparation of duloxetine hydrochloride and preparation method thereof
GR1008228B (en) * 2013-04-23 2014-06-16 "Φαρματεν Α.Β.Ε.Ε.", Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof
EP2813218B1 (en) 2013-06-14 2022-08-24 Shin-Etsu Chemical Co., Ltd. Method for producing aqueous enteric coating liquid, solid preparation, and method for producing same
CN103393615B (en) * 2013-07-24 2015-07-15 海南华益泰康药业有限公司 Duloxetine enteric pellet and preparation method thereof
PL224543B1 (en) 2013-08-21 2017-01-31 Pabianickie Zakłady Farm Polfa Spółka Akcyjna Duloxetine enteric tablet
UA117260C2 (en) 2013-10-29 2018-07-10 Тиллоттс Фарма АГ A delayed release drug formulation
EP3065720A1 (en) 2013-11-04 2016-09-14 Capsugel Belgium NV Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
US9782356B2 (en) * 2014-05-20 2017-10-10 Dow Global Technologies Llc Capsule shells comprising an esterified cellulose ether
WO2016029215A1 (en) * 2014-08-22 2016-02-25 Medipath, Inc. Compositions and methods for cannabinoid coatings for use in drug delivery
US10471152B2 (en) * 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
US20170182070A1 (en) 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
US9668975B2 (en) 2014-10-14 2017-06-06 PharmaDax Inc. Method of preparing drug agglomerate
CN105726488B (en) * 2014-12-08 2020-10-20 上海爱科百发生物医药技术有限公司 Enteric-coated pellet containing respiratory syncytial virus inhibitor and preparation method thereof
KR101625344B1 (en) 2015-12-21 2016-06-08 주식회사 유영제약 Pharmaceutical compositions comprising celecoxib and duloxetine
CN105534949A (en) * 2016-01-06 2016-05-04 北京修正创新药物研究院有限公司 Duloxetine hydrochloride enteric mini-pill preparation
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP6815109B2 (en) * 2016-06-23 2021-01-20 キョーリンリメディオ株式会社 A pharmaceutical composition containing duloxetine or a pharmaceutically acceptable salt thereof as an active ingredient.
JP6856326B2 (en) * 2016-07-15 2021-04-07 富士化学工業株式会社 Intestinal release particle composition
CN106166144A (en) * 2016-08-12 2016-11-30 海南合瑞制药股份有限公司 A kind of duloxetine hydrochloride enteric coated capsule pharmaceutical composition
JP2018172361A (en) * 2016-10-14 2018-11-08 大原薬品工業株式会社 Solid preparation containing duloxetine, having improved light stability
US9839626B1 (en) * 2016-12-14 2017-12-12 Sun Pharmaceutical Industries Limited Duloxetine sprinkles
JP7072431B2 (en) * 2017-04-14 2022-05-20 富士化学工業株式会社 Tablets and their manufacturing methods
JP6972674B2 (en) * 2017-06-06 2021-11-24 ニプロ株式会社 Oral pharmaceutical product
JP2020029447A (en) * 2018-06-25 2020-02-27 大原薬品工業株式会社 Granule containing enteric polymer and anti-attachment agent
CN110420195B (en) * 2018-10-25 2022-12-06 上海上药中西制药有限公司 Duloxetine hydrochloride enteric-coated preparation, main medicine layer and suspension thereof, isolation layer and coating liquid thereof, and preparation method thereof
JP7050714B2 (en) * 2019-04-04 2022-04-08 信越化学工業株式会社 Method for Producing Composition for Enteric Coating and Solid Formula
JP2020189815A (en) * 2019-05-23 2020-11-26 東和薬品株式会社 Duloxetine preparation and method of stabilizing the same
US20220265659A1 (en) 2019-09-02 2022-08-25 Inserm (Institut National De La Santé Et De Al Recherche Médicale) Methods and compositions for treating pax6-deficiency related disease
WO2021126099A1 (en) * 2019-12-18 2021-06-24 Santa Farma İlaç Sanayi̇ A.Ş. An enteric coated pellet comprising duloxetine hydrochloride with optimized degrees of neutralization
WO2021126098A1 (en) * 2019-12-18 2021-06-24 Santa Farma İlaç Sanayi̇ A.Ş. Gastro-resistant pellet comprising duloxetine
WO2022115054A1 (en) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Enteric coated duloxetine compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CH649216A5 (en) * 1979-08-16 1985-05-15 Sandoz Ag METHOD FOR APPLYING AN ACID-RESISTANT FILM TO A MEDICINAL CORE AND SOLID UNIT DOSAGE FORM WITH ACID-ACID RESISTANT FILM.
US5019302A (en) 1986-03-12 1991-05-28 Washington University Technology Associates, Inc. Method for granulation
US5100592A (en) 1986-03-12 1992-03-31 Washington University Technology Associated, Inc. Method and apparatus for granulation and granulated product
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
JP2773959B2 (en) * 1990-07-10 1998-07-09 信越化学工業株式会社 Colon release solid preparation
JPH04346930A (en) * 1991-05-25 1992-12-02 Sumitomo Pharmaceut Co Ltd Stable aspirin enteric tablet
ZA93694B (en) * 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis

Similar Documents

Publication Publication Date Title
RU95113118A (en) Intestinal Duloxetine Granules
US4755385A (en) Oral pharmaceutical preparations containing 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin
CA2059865A1 (en) Pharmaceutical Compositions Containing Orally Absorbable Glycosaminoglycans
RU94046268A (en) Omeprazole granules and method of their preparing
CA2346988A1 (en) Pharmaceutical formulation comprising omeprazole
AR240251A1 (en) METHOD TO PREPARE A COMPOSITION FOR TREATMENT OF VIRAL INFECTIONS AND A METHOD TO SYNTHESIZE 3 'AZIDO 2', 3 'DIDEOXIURIDINA INTENDED FOR THE PREPARATION OF SUCH COMPOSITION.
CA2257121A1 (en) Methods and compositions for treating urinary incontinence using optically pure (s)-oxybutynin
GR3032101T3 (en) Vehicles for oral administration of a specific pharmaceutically active acid labile substance.
CA2136848A1 (en) Pharmaceutically acceptable fixed-dried human blood platelets
CA2152795A1 (en) Readily available konjac glucomannan sustained release excipient
CA2232855A1 (en) Pharmaceutical formulation
ATE23110T1 (en) DIVISIBLE DELAYED-RELEASE TABLET AND METHOD OF MANUFACTURE THEREOF.
CA2065773A1 (en) Gastroresistant pharmaceutical formulations for oral administration containing bile acids
RU94035739A (en) Pharmaceutical composition containing nifedipin and method of its preparing
US4808416A (en) Preparation of a slow-release drug
PH24376A (en) Spray dried acetominophen
NO865195L (en) PROCEDURE FOR THE MANUFACTURE OF A RETARD PREPARATION OF IBUPROFEN.
FR2598420B1 (en) NOVEL RETINOIC ANTIBIOTICS ESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM
PT91612A (en) PROCESS FOR THE PREPARATION PF 2-AZA-4 (ALKOXYCARBONYL> SPIRO <4,5> DECAN-3-ON AND OF HIS OWN ACID DERIVATIVE 1- (AMINOMETHYL) -CYCLO-HEXANE-ACETIC
DE3172570D1 (en) Serpentine, alstonine and sempervirine drugs for the specific inhibition of tumurous and cancerous cells
FR2628103B1 (en) NOVEL PYRETHRINOID ESTERS CARRYING AN INDANYL CORE, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS PESTICIDES
NO976056D0 (en) Process for the preparation of enantiomerically pure azetidine-2-carboxylic acid
ZA892871B (en) Microbeads of ditiazem a process for their manufacture and a sustained-release pharmaceutical composition containing them
EP0145558A2 (en) Galenic forms of sulpiride for oral administration
AU576215B2 (en) ((1,3,-dioxo-1,3 propandiyl) diimino) bis-benzoic acid derivatives and their pharmaceutical use